{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:28:50Z","timestamp":1790306930632,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.jconrel.2007.11.005","type":"journal-article","created":{"date-parts":[[2007,11,26]],"date-time":"2007-11-26T21:27:10Z","timestamp":1196112430000},"page":"50-58","source":"Crossref","is-referenced-by-count":141,"title":["Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: A comparison of whole monoclonal antibody, Fab\u2032 fragments and single chain Fv"],"prefix":"10.1016","volume":"126","author":[{"given":"Wilson W.K.","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa M.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jconrel.2007.11.005_bib1","first-page":"4730","article-title":"Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers","volume":"43","author":"Gabizon","year":"1983","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.jconrel.2007.11.005_bib2","first-page":"3698","article-title":"Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU\/M Wsl rat","volume":"44","author":"van Hoesel","year":"1984","journal-title":"Cancer Res."},{"issue":"12 Pt 1","key":"10.1016\/j.jconrel.2007.11.005_bib3","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy; mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2007.11.005_bib4","first-page":"135","article-title":"Passive tumor targeting of soluble macromolecules and drug conjugates","volume":"9","author":"Seymour","year":"1992","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"issue":"1\u20133","key":"10.1016\/j.jconrel.2007.11.005_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0168-3659(97)00237-X","article-title":"Delivery of molecular and cellular medicine to solid tumors","volume":"53","author":"Jain","year":"1998","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.jconrel.2007.11.005_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/187152006778699121","article-title":"Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer","volume":"6","author":"Allen","year":"2006","journal-title":"Anticancer Agents Med. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2007.11.005_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/j.1552-4604.1996.tb04152.x","article-title":"Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumour localization, and safety in patients with AIDS-related Kaposi's sarcoma","volume":"36","author":"Northfelt","year":"1996","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl 9","key":"10.1016\/j.jconrel.2007.11.005_bib8","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0959-8049(01)00330-6","article-title":"Phase III data on Caelyx in ovarian cancer","volume":"37","author":"Muggia","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.jconrel.2007.11.005_bib9","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc903","article-title":"Ligand-targeted therapeutics in anticancer therapy","volume":"2","author":"Allen","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2007.11.005_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbamem.2005.02.007","article-title":"Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity","volume":"1711","author":"Laginha","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.jconrel.2007.11.005_bib11","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/1078-0432.CCR-03-0041","article-title":"Improved therapeutic responses in a xenograft model of human B-lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments","volume":"10","author":"Sapra","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2007.11.005_bib12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4049\/jimmunol.131.1.244","article-title":"B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes","volume":"131","author":"Nadler","year":"1983","journal-title":"J. Immunol."},{"issue":"17","key":"10.1016\/j.jconrel.2007.11.005_bib13","first-page":"4906","article-title":"Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies","volume":"49","author":"Press","year":"1989","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.jconrel.2007.11.005_bib14","first-page":"7190","article-title":"Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs","volume":"62","author":"Sapra","year":"2002","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2007.11.005_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbamem.2006.09.004","article-title":"Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells","volume":"1768","author":"Cheng","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.jconrel.2007.11.005_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-5793(97)00905-8","article-title":"Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo","volume":"413","author":"Maruyama","year":"1997","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2007.11.005_bib17","first-page":"86","article-title":"Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice","volume":"63","author":"Pastorino","year":"2003","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.jconrel.2007.11.005_bib18","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.4049\/jimmunol.138.9.2793","article-title":"CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation","volume":"138","author":"Pezzutto","year":"1987","journal-title":"J. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2007.11.005_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0014-5793(99)00713-9","article-title":"Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding","volume":"453","author":"Le Gall","year":"1999","journal-title":"FEBS Lett."},{"issue":"6","key":"10.1016\/j.jconrel.2007.11.005_bib20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF02535225","article-title":"Use of radiolabelled hexadecyl cholesterol ether as a liposome marker","volume":"17","author":"Pool","year":"1982","journal-title":"Lipids"},{"issue":"1","key":"10.1016\/j.jconrel.2007.11.005_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0167-4889(87)90047-4","article-title":"Processing of different liposomal markers after in vitro uptake of immunoglobulin-coated liposomes by rat liver macrophages","volume":"931","author":"Derksen","year":"1987","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2007.11.005_bib22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3109\/08982109409037057","article-title":"Ammonium sulphate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandosomes","volume":"4","author":"Bolotin","year":"1994","journal-title":"J. Liposome Res."},{"issue":"2","key":"10.1016\/j.jconrel.2007.11.005_bib23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/08982109909024786","article-title":"Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma cells","volume":"9","author":"Lopes de Menezes","year":"1999","journal-title":"J. Liposome Res."},{"issue":"2","key":"10.1016\/j.jconrel.2007.11.005_bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0005-2736(01)00357-1","article-title":"In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion technique","volume":"1513","author":"Iden","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"issue":"15","key":"10.1016\/j.jconrel.2007.11.005_bib25","first-page":"3320","article-title":"In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma","volume":"58","author":"Lopes de Menezes","year":"1998","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2007.11.005_bib26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0014-5793(99)01320-4","article-title":"A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs","volume":"460","author":"Ishida","year":"1999","journal-title":"FEBS Lett."},{"issue":"8","key":"10.1016\/j.jconrel.2007.11.005_bib27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1461-5347(00)00280-7","article-title":"Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries","volume":"3","author":"Nielsen","year":"2000","journal-title":"Pharm. Sci. Technol. Today"},{"issue":"1","key":"10.1016\/j.jconrel.2007.11.005_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/sj.bjc.6600423","article-title":"Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes","volume":"87","author":"Marty","year":"2002","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2007.11.005_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/10611860600691049","article-title":"EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells","volume":"14","author":"Mamot","year":"2006","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.jconrel.2007.11.005_bib30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10717540601036831","article-title":"Cellular association and cytotoxicity of doxorubicin-loaded immunoliposomes targeted via Fab' fragments of an anti-CD74 antibody","volume":"14","author":"Lundberg","year":"2007","journal-title":"Drug Deliv."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2007.11.005_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2007.04.013","article-title":"Cytoskeletal-antigen specific immunoliposome-targeted in vivo preservation of myocardial viability","volume":"120","author":"Khaw","year":"2007","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2007.11.005_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08982100601186474","article-title":"Antinucleosome antibody-modified liposomes and lipid\u2013core micelles for tumor-targeted delivery of therapeutic and diagnostic agents","volume":"17","author":"Elbayoumi","year":"2007","journal-title":"J. Liposome Res."},{"issue":"5","key":"10.1016\/j.jconrel.2007.11.005_bib33","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1006\/jmbi.2000.4265","article-title":"Stability engineering of antibody single-chain Fv fragments","volume":"305","author":"Worn","year":"2001","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2007.11.005_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jmb.2005.12.058","article-title":"Thioredoxin fusions increase folding of single chain Fv antibodies in the cytoplasm of Escherichia coli: evidence that chaperone activity is the prime effect of thioredoxin","volume":"357","author":"Jurado","year":"2006","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2007.11.005_bib35","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.pep.2006.08.009","article-title":"Optimisation of production of a domoic acid-binding scFv antibody fragment in Escherichia coli using molecular chaperones and functional immobilisation on a mesoporous silicate support","volume":"52","author":"Hu","year":"2007","journal-title":"Protein Expr. Purif."},{"issue":"2","key":"10.1016\/j.jconrel.2007.11.005_bib36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/1389203003381397","article-title":"Phage display of antibody fragments","volume":"1","author":"Pini","year":"2000","journal-title":"Curr. Protein Pept. Sci."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2007.11.005_bib37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jim.2004.11.008","article-title":"Selecting for antibody scFv fragments with improved stability using phage display with denaturation under reducing conditions","volume":"296","author":"Brockmann","year":"2005","journal-title":"J. Immunol. Methods"},{"issue":"10","key":"10.1016\/j.jconrel.2007.11.005_bib38","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00109-007-0208-z","article-title":"Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer","volume":"85","author":"Liu","year":"2007","journal-title":"J. Mol. Med."},{"issue":"1\u20133","key":"10.1016\/j.jconrel.2007.11.005_bib39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0167-4889(02)00256-2","article-title":"Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis","volume":"1591","author":"Nielsen","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.jconrel.2007.11.005_bib40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1021\/bp049840y","article-title":"Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. gram-scale production and purification","volume":"21","author":"Nellis","year":"2005","journal-title":"Biotechnol. Prog."},{"issue":"2","key":"10.1016\/j.jconrel.2007.11.005_bib41","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.canlet.2005.04.029","article-title":"Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy","volume":"235","author":"Marty","year":"2006","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.jconrel.2007.11.005_bib42","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1158\/1535-7163.MCT-07-0140","article-title":"Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells","volume":"6","author":"Roth","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2007.11.005_bib43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/prot.340160107","article-title":"Recombinant antineuraminidase single chain antibody: expression, characterization, and crystallization in complex with antigen","volume":"16","author":"Malby","year":"1993","journal-title":"Proteins"},{"issue":"34","key":"10.1016\/j.jconrel.2007.11.005_bib44","doi-asserted-by":"crossref","first-page":"25722","DOI":"10.1016\/S0021-9258(19)74449-4","article-title":"Binding affinity and inhibitory properties of a single-chain anti-T cell receptor antibody","volume":"268","author":"Schodin","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.jconrel.2007.11.005_bib45","first-page":"3154","article-title":"Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.","volume":"63","author":"Mamot","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2007.11.005_bib46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0076-6879(04)87003-4","article-title":"Folate receptor-mediated targeting of liposomal drugs to cancer cells","volume":"387","author":"Stephenson","year":"2004","journal-title":"Meth. Enzymol."},{"issue":"2","key":"10.1016\/j.jconrel.2007.11.005_bib47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0005-2736(91)90201-I","article-title":"Pharmacokinetics of Stealth versus conventional liposomes: effect of dose","volume":"1068","author":"Allen","year":"1991","journal-title":"Biochim. Biophys. Acta"},{"issue":"24","key":"10.1016\/j.jconrel.2007.11.005_bib48","doi-asserted-by":"crossref","first-page":"11631","DOI":"10.1158\/0008-5472.CAN-05-1093","article-title":"Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo","volume":"65","author":"Mamot","year":"2005","journal-title":"Cancer Res."},{"issue":"13","key":"10.1016\/j.jconrel.2007.11.005_bib49","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","article-title":"Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models","volume":"66","author":"Kirpotin","year":"2006","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.jconrel.2007.11.005_bib50","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nbt1142","article-title":"Engineered antibody fragments and the rise of single domains","volume":"23","author":"Holliger","year":"2005","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2007.11.005_bib51","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1021\/bp049839z","article-title":"Preclinical manufacture of anti-HER2 liposome-inserting, scFv\u2013PEG\u2013lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis","volume":"21","author":"Nellis","year":"2005","journal-title":"Biotechnol. Prog."},{"issue":"5","key":"10.1016\/j.jconrel.2007.11.005_bib52","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00253-002-1158-6","article-title":"Overview of tag protein fusions: From molecular and biochemical fundamentals to commercial systems","volume":"60","author":"Terpe","year":"2003","journal-title":"Appl. Microbiol. Biotechnol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365907006293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365907006293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T23:08:57Z","timestamp":1684105737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365907006293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0168365907006293"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2007.11.005","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}